Is MOTS-c legal in Australia?

MOTS-c is not ARTG-registered. Research availability does not establish Australian approval or permission for human use.

Does MOTS-c replace metformin or GLP-1 drugs?

No established evidence supports replacing prescribed medicines with MOTS-c. Questions about current treatment belong with the treating doctor.

Mitochondrial peptide — metabolic

MOTS-c in Australia: Legal Status & Evidence

16-amino-acid mitochondrial-derived peptide investigated for metabolic and insulin-sensitivity support.

Short answer: MOTS-c is not an ARTG-registered finished medicine. A website listing does not establish safety, clinical suitability or lawful supply.

Overview

MOTS-c is a mitochondrial-derived peptide studied in cellular metabolic signalling. Much of the published work is preclinical; it does not establish clinical benefit or long-term human safety.

Australian regulatory status

MOTS-c is not an ARTG-registered finished medicine. A website listing does not establish safety, clinical suitability or lawful supply.

Registration and exceptional access are different

ARTG registration applies to a specific product and its approved indications. An eligible unapproved medicine may instead require a TGA application and approval before supply, or Authorised Prescriber authorisation. Neither pathway is an endorsement, a finding of suitability for everyone, or an override of supply prohibitions.

Evidence and uncertainty

Laboratory and animal findings cannot establish patient outcomes. Small or early studies may not identify uncommon harms, interactions or long-term risks. Research on one formulation or population cannot automatically be applied to another. This page does not rank treatments or recommend a medicine.

Safety questions for an individual assessment

A registered doctor considers symptoms, medical history, current medicines, allergies and any necessary investigations. Pregnancy, breastfeeding, cancer history and other health conditions may change the assessment. Potential interactions and the limits of available evidence need to be discussed. Do not start, combine or adjust medicines based on online information.

Unregulated products and importation

A research-only label does not establish quality or lawful therapeutic supply. Identity, concentration and sterility may be unverified. Personal importation has conditions and restrictions; check the official TGA guidance rather than relying on a seller's claims. A prescription is not an automatic exemption from every restriction.

Clinical decisions and follow-up

Whether any treatment is appropriate is a decision for a registered doctor after an individual assessment. Monitoring and follow-up depend on the person and the product; there is no universal timetable or promised outcome. Questions about symptoms or suspected adverse effects should be directed to a health practitioner. In an emergency, call 000.

Indications reviewed at consultation

Medical history, allergies and previous treatment
Current medicines and potential interactions
Pregnancy, breastfeeding and relevant health conditions

Administration

MOTS-c remains an experimental research topic, not an established substitute for medical care.

Cautions

Not for use in pregnancy, breastfeeding, or active cancer. Caution if you have insulin-treated diabetes. Long-term human safety data is limited.

Frequently asked questions

Is MOTS-c legal in Australia?: MOTS-c is not ARTG-registered. Research availability does not establish Australian approval or permission for human use.
Does MOTS-c replace metformin or GLP-1 drugs?: No established evidence supports replacing prescribed medicines with MOTS-c. Questions about current treatment belong with the treating doctor.

Educational content only. Whether any treatment is appropriate, and whether it can lawfully be supplied in Australia, is a decision for a registered doctor and the TGA.

General information only, not medical advice. The treating doctor decides whether any treatment is appropriate.

Important information

Official sources — regulatory context

These sources explain medicine regulation, access and health advertising requirements; they do not endorse this site. An educational disclaimer does not establish compliance or replace advice from a registered clinician.

Related peptides

Unapproved peptide

BPC-157

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

CJC-1295 + Ipamorelin

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

Ipamorelin

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

AOD-9604

Evidence limitations and individual safety require clinical assessment. Registration and lawful supply must be checked; this information is not a treatment recommendation.

Australian consultation information by city

Questions about your options?

Learn how a telehealth consultation with an AHPRA-registered Australian doctor works. Whether any treatment is appropriate is a decision your doctor makes based on your individual clinical needs.

How Australian access pathways work